OSBPL10

Summary

OSBPL10 (oxysterol binding protein like 10, HGNC:16395) is a protein-coding gene on chromosome 3p23, encoding Oxysterol-binding protein-related protein 10 (Q9BXB5). Probable lipid transporter involved in lipid countertransport between the endoplasmic reticulum and the plasma membrane.

This gene encodes a member of the oxysterol-binding protein (OSBP) family, a group of intracellular lipid receptors. Like most members, the encoded protein contains an N-terminal pleckstrin homology domain and a highly conserved C-terminal OSBP-like sterol-binding domain. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 114884 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 214 total
• MANE Select transcript: NM_017784

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16395
Approved symbol	OSBPL10
Name	oxysterol binding protein like 10
Location	3p23
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000144645
Ensembl biotype	protein_coding
OMIM	606738
Entrez	114884

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 12 protein_coding_CDS_not_defined, 10 protein_coding, 2 retained_intron

ENST00000396556, ENST00000428241, ENST00000429492, ENST00000438237, ENST00000452791, ENST00000463504, ENST00000465626, ENST00000466604, ENST00000467598, ENST00000467647, ENST00000467955, ENST00000469557, ENST00000472175, ENST00000479173, ENST00000479396, ENST00000480671, ENST00000485205, ENST00000490009, ENST00000673388, ENST00000698199, ENST00000911815, ENST00000911816, ENST00000959571, ENST00000959572

RefSeq mRNA: 2 — MANE Select: NM_017784 NM_001174060, NM_017784

CCDS: CCDS2651, CCDS54559

Canonical transcript exons

ENST00000396556 — 12 exons

Exon	Start	End
ENSE00001525446	31660825	31662116
ENSE00001525447	31980899	31981262
ENSE00001724748	31683634	31684114
ENSE00001737189	31664079	31664232
ENSE00001746442	31668642	31668824
ENSE00001759198	31670797	31670983
ENSE00003498172	31702359	31702508
ENSE00003500607	31876433	31876512
ENSE00003525332	31747910	31748120
ENSE00003579736	31830040	31830231
ENSE00003581525	31879655	31879830
ENSE00003791179	31733257	31733411

Expression profiles

Bgee: expression breadth ubiquitous, 264 present calls, max score 97.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.2551 / max 176.4356, expressed in 1385 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
41585	5.6016	1321
41590	1.6333	562
41588	0.2994	122
41586	0.1704	84
41589	0.1582	80
41583	0.1491	55
41587	0.1335	67
41581	0.0319	8
41582	0.0270	6
41578	0.0190	3

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.19	gold quality
oocyte	CL:0000023	96.99	gold quality
right testis	UBERON:0004534	95.06	gold quality
left testis	UBERON:0004533	95.00	gold quality
saphenous vein	UBERON:0007318	94.65	gold quality
decidua	UBERON:0002450	94.41	gold quality
testis	UBERON:0000473	93.24	gold quality
palpebral conjunctiva	UBERON:0001812	92.83	gold quality
colonic epithelium	UBERON:0000397	92.29	gold quality
cauda epididymis	UBERON:0004360	92.15	gold quality
epithelium of nasopharynx	UBERON:0001951	91.39	gold quality
mucosa of urinary bladder	UBERON:0001259	91.37	gold quality
superficial temporal artery	UBERON:0001614	91.31	gold quality
pigmented layer of retina	UBERON:0001782	91.29	gold quality
tongue squamous epithelium	UBERON:0006919	91.13	silver quality
esophagus squamous epithelium	UBERON:0006920	90.91	gold quality
urinary bladder	UBERON:0001255	90.90	gold quality
nephron tubule	UBERON:0001231	90.55	gold quality
epithelium of esophagus	UBERON:0001976	90.52	gold quality
renal glomerulus	UBERON:0000074	90.46	gold quality
placenta	UBERON:0001987	90.44	gold quality
metanephric glomerulus	UBERON:0004736	90.25	gold quality
hair follicle	UBERON:0002073	89.79	silver quality
mucosa of paranasal sinus	UBERON:0005030	89.27	gold quality
tonsil	UBERON:0002372	88.93	gold quality
squamous epithelium	UBERON:0006914	88.28	gold quality
gingival epithelium	UBERON:0001949	87.59	gold quality
amniotic fluid	UBERON:0000173	87.48	gold quality
urethra	UBERON:0000057	87.41	gold quality
gingiva	UBERON:0001828	87.41	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	29.00
E-ANND-3	yes	9.42
E-ENAD-27	yes	4.08

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

131 targeting OSBPL10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867

Literature-anchored findings (GeneRIF, showing 6)

• Analysis of variants in three genes encoding OSBP homologues in families with familial low high-density lipoprotein levels or familial combined hyperlipidemia revealed linkage of OSBPL10 single-nucleotide polymorphisms with high triglyceride trait. (PMID:19554302)
• Overall, the rs2290532 (D254N) polymorphism in OSBPL10 may predispose individuals to hyper-LDL cholesterolemia. (PMID:20224571)
• Single-nucleotide polymorphisms in OSBPL10 is associated with peripheral arterial disease. (PMID:20610895)
• Data indicate that the apoB-100 secretion phenotype is replicated in HepG2 cells transduced with the ORP10 shRNA lentiviruses. (PMID:22906437)
• findings reveal that circOSBPL10 may serve as a new proliferation factor and prognostic marker in gastric cancer (PMID:31409903)
• PI4P/PS countertransport by ORP10 at ER-endosome membrane contact sites regulates endosome fission. (PMID:34817532)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	osbpl10b	ENSDARG00000040027
danio_rerio		ENSDARG00000099747
mus_musculus	Osbpl10	ENSMUSG00000040875
rattus_norvegicus	Osbpl10	ENSRNOG00000011435
drosophila_melanogaster	CG3860	FBGN0034951
caenorhabditis_elegans		WBGENE00008832

Paralogs (11): OSBPL7 (ENSG00000006025), OSBPL5 (ENSG00000021762), OSBPL3 (ENSG00000070882), OSBPL6 (ENSG00000079156), OSBPL8 (ENSG00000091039), OSBP (ENSG00000110048), OSBPL9 (ENSG00000117859), OSBPL2 (ENSG00000130703), OSBPL1A (ENSG00000141447), OSBPL11 (ENSG00000144909), OSBP2 (ENSG00000184792)

Protein

Protein identifiers

Oxysterol-binding protein-related protein 10 — Q9BXB5 (reviewed: Q9BXB5)

All UniProt accessions (5): Q9BXB5, A0A5F9ZH75, A0A8V8TM06, H7C199, H7C487

UniProt curated annotations — full annotation on UniProt →

Function. Probable lipid transporter involved in lipid countertransport between the endoplasmic reticulum and the plasma membrane. Its ability to bind phosphatidylserine, suggests that it specifically exchanges phosphatidylserine with phosphatidylinositol 4-phosphate (PI4P), delivering phosphatidylserine to the plasma membrane in exchange for PI4P. Plays a role in negative regulation of lipid biosynthesis. Negatively regulates APOB secretion from hepatocytes. Binds cholesterol and acidic phospholipids. Also binds 25-hydroxycholesterol. Binds phosphatidylserine.

Subunit / interactions. Interacts with OSBPL9. Interacts with DIAPH1.

Subcellular location. Cytoplasm. Cytoskeleton.

Domain organisation. The C-terminal region binds cholesterol, 25-hydroxysterol and acidic phospholipids and is required for localization to microtubules. The PH domain selectively interacts with phosphatidylinositol-4-phosphate.

Polymorphism. Polymorphisms are associated with dyslipidemia. Variant Asn-254 is associated with LDL-cholesterol levels in Japanese population. Association with peripheral arterial disease has also been observed.

Similarity. Belongs to the OSBP family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BXB5-1	1	yes
Q9BXB5-2	2

RefSeq proteins (2): NP_001167531, NP_060254* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000648	Oxysterol-bd	Family
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR018494	Oxysterol-bd_CS	Conserved_site
IPR037239	OSBP_sf	Homologous_superfamily
IPR041680	PH_8	Domain

Pfam: PF01237, PF15409

UniProt features (33 total): modified residue 10, binding site 9, compositionally biased region 5, region of interest 4, chain 1, domain 1, splice variant 1, sequence variant 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BXB5-F1	75.03	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (9): 413–418; 413–418; 477–480; 480; 535–536; 561; 721; 725; 729

Post-translational modifications (10): 29, 30, 38, 57, 60, 64, 196, 201, 209, 223

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1482801	Acyl chain remodelling of PS

MSigDB gene sets: 186 (showing top): GOBP_PHOSPHATIDYLSERINE_ACYL_CHAIN_REMODELING, SHEPARD_BMYB_MORPHOLINO_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_VACUOLE_ORGANIZATION, GOCC_VACUOLAR_MEMBRANE, TTTGTAG_MIR520D, MODULE_511, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, MODULE_453, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, CAGCTG_AP4_Q5, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, GOBP_LIPID_HOMEOSTASIS, GOBP_GLYCEROLIPID_METABOLIC_PROCESS

GO Biological Process (5): phosphatidylserine acyl-chain remodeling (GO:0036150), intermembrane lipid transfer (GO:0120009), lipid metabolic process (GO:0006629), lipid transport (GO:0006869), phospholipid transport (GO:0015914)

GO Molecular Function (6): phosphatidylserine binding (GO:0001786), obsolete phospholipid transporter activity (GO:0005548), cholesterol binding (GO:0015485), lipid carrier activity (GO:0005319), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (5): cytosol (GO:0005829), cytoskeleton (GO:0005856), membrane (GO:0016020), transporter complex (GO:1990351), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
lipid transport	2
binding	2
phosphatidylserine metabolic process	1
membrane organization	1
primary metabolic process	1
transport	1
lipid localization	1
organophosphate ester transport	1
phospholipid binding	1
anion binding	1
modified amino acid binding	1
sterol binding	1
alcohol binding	1
molecular carrier activity	1
cytoplasm	1
intracellular membraneless organelle	1
protein-containing complex	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1042 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OSBPL10	PLEK2	Q9NYT0	615
OSBPL10	PLEK	P08567	603
OSBPL10	APOB	P04114	528
OSBPL10	ZNF860	A6NHJ4	507
OSBPL10	NIBAN1	Q9BZQ8	479
OSBPL10	RXRA	P19793	478
OSBPL10	OSBP	P22059	473
OSBPL10	OSBP2	Q969R2	459
OSBPL10	PIK3AP1	Q6ZUJ8	430
OSBPL10	OGDHL	Q9ULD0	427
OSBPL10	ACTC1	P04270	415
OSBPL10	VAPA	Q9P0L0	402
OSBPL10	ANKRD22	Q5VYY1	392
OSBPL10	STT3B	Q8TCJ2	390
OSBPL10	GADL1	Q6ZQY3	386

IntAct

48 interactions, top by confidence:

A	B	Type	Score
OSBPL9	VAPB	psi-mi:“MI:0914”(association)	0.790
VAPB	FAM83G	psi-mi:“MI:0914”(association)	0.730
OSBPL11	VAPB	psi-mi:“MI:0914”(association)	0.730
VAPA	FAM83G	psi-mi:“MI:0914”(association)	0.640
VAPA	PITPNM1	psi-mi:“MI:0914”(association)	0.640
OSBPL10	OSBPL9	psi-mi:“MI:0915”(physical association)	0.630
	OSBPL10	psi-mi:“MI:0915”(physical association)	0.560
YWHAG	SHTN1	psi-mi:“MI:0914”(association)	0.560
HSPB8	VWA8	psi-mi:“MI:0914”(association)	0.530
	OSBPL10	psi-mi:“MI:0407”(direct interaction)	0.440
PCNT	OSBPL10	psi-mi:“MI:0915”(physical association)	0.400
	OSBPL10	psi-mi:“MI:0915”(physical association)	0.400
IKBKG	OSBPL10	psi-mi:“MI:0915”(physical association)	0.370
VAPA		psi-mi:“MI:0914”(association)	0.350
Tgs1	EFCAB5	psi-mi:“MI:0914”(association)	0.350
VAPA	FAM83G	psi-mi:“MI:0914”(association)	0.350

BioGRID (77): OSBPL10 (Affinity Capture-MS), OSBPL10 (Affinity Capture-MS), OSBPL10 (Affinity Capture-MS), OSBPL10 (Affinity Capture-MS), OSBPL10 (Affinity Capture-MS), OSBPL10 (Proximity Label-MS), OSBPL10 (Proximity Label-MS), OSBPL10 (Affinity Capture-RNA), OSBPL10 (Proximity Label-MS), OSBPL10 (Proximity Label-MS), OSBPL10 (Proximity Label-MS), OSBPL10 (Proximity Label-MS), OSBPL10 (Proximity Label-MS), OSBPL10 (Proximity Label-MS), OSBPL10 (Proximity Label-MS)

ESM2 similar proteins: A2AHJ4, A4IID4, A9JRL3, A9X1A0, B0KWC1, B1MTG7, B2KI64, B2RQE8, B3EX61, B4UT09, G5EBH0, O00418, O00763, O02697, O02810, O08561, O08796, O08874, P25455, P48736, P70531, Q07139, Q28C33, Q49GP3, Q4U2V3, Q5R585, Q641K1, Q6DD21, Q6F6B3, Q6GN16, Q6NRE7, Q6PCL9, Q80X66, Q86X55, Q8BKC8, Q8BPM2, Q8CI95, Q8IVH8, Q924I2, Q99JP0

Diamond homologs: A0A2Z4HQ03, A2A8Z1, B9EJ86, O43021, O74178, O80866, P0C199, P35844, P38755, Q02201, Q0IJ05, Q54NM4, Q5M7Y0, Q5R6M6, Q5R9W4, Q6NRZ4, Q6P3Q6, Q6VVX2, Q86KG4, Q8BX94, Q8CI95, Q96SU4, Q9BXB4, Q9BXB5, Q9BZF1, Q9EQG9, Q9ER64, Q9GKI7, Q9H0X9, Q9H1P3, Q9UUA1, Q9UW21, Q9UW25, Q9Y5P4, S4R1M9, O94512, Q12451, Q54PS9, Q8S8P9, Q9SVZ9

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

214 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	179
Likely benign	14
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

4421 predictions. Top by Δscore:

Variant	Effect	Δscore
3:31664074:GTTA:G	donor_loss	1.0000
3:31664075:TTAC:T	donor_loss	1.0000
3:31664076:TACCT:T	donor_loss	1.0000
3:31664077:A:T	donor_loss	1.0000
3:31664077:ACCT:A	donor_gain	1.0000
3:31664078:C:G	donor_loss	1.0000
3:31664078:CCTC:C	donor_gain	1.0000
3:31664080:T:TA	donor_gain	1.0000
3:31664102:T:TA	donor_gain	1.0000
3:31664103:C:A	donor_gain	1.0000
3:31664129:T:TA	donor_gain	1.0000
3:31664228:GGTTC:G	acceptor_gain	1.0000
3:31664229:GTTCC:G	acceptor_loss	1.0000
3:31664230:TTC:T	acceptor_gain	1.0000
3:31664230:TTCCT:T	acceptor_loss	1.0000
3:31664231:TC:T	acceptor_gain	1.0000
3:31664231:TCC:T	acceptor_loss	1.0000
3:31664232:CC:C	acceptor_gain	1.0000
3:31664232:CCTGG:C	acceptor_loss	1.0000
3:31664233:C:A	acceptor_loss	1.0000
3:31664233:C:CC	acceptor_gain	1.0000
3:31664234:T:A	acceptor_loss	1.0000
3:31664239:A:AC	acceptor_gain	1.0000
3:31664239:A:C	acceptor_gain	1.0000
3:31664242:C:CT	acceptor_gain	1.0000
3:31664243:G:C	acceptor_gain	1.0000
3:31670987:C:CT	acceptor_gain	1.0000
3:31670987:C:T	acceptor_gain	1.0000
3:31670988:A:T	acceptor_gain	1.0000
3:31702354:CCTA:C	donor_loss	1.0000

AlphaMissense

4994 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:31664166:C:A	K721N	1.000
3:31664166:C:G	K721N	1.000
3:31668763:A:G	W659R	1.000
3:31668763:A:T	W659R	1.000
3:31668822:A:T	V639D	1.000
3:31670920:C:G	R597P	1.000
3:31683672:A:G	F563S	1.000
3:31702366:A:G	L413S	1.000
3:31702384:A:G	L407P	1.000
3:31980899:C:A	R94M	1.000
3:31980909:A:G	W91R	1.000
3:31980909:A:T	W91R	1.000
3:31664179:G:T	A717D	0.999
3:31664203:A:G	L709P	0.999
3:31664223:C:A	W702C	0.999
3:31664223:C:G	W702C	0.999
3:31664225:A:G	W702R	0.999
3:31664225:A:T	W702R	0.999
3:31668645:G:A	S698F	0.999
3:31668761:C:A	W659C	0.999
3:31668761:C:G	W659C	0.999
3:31668762:C:G	W659S	0.999
3:31668768:C:T	G657E	0.999
3:31668817:C:G	A641P	0.999
3:31670833:A:G	F626S	0.999
3:31670914:A:G	I599T	0.999
3:31670914:A:T	I599N	0.999
3:31670918:A:G	S598P	0.999
3:31670923:G:T	A596D	0.999
3:31670929:G:T	A594D	0.999

dbSNP variants (sampled 300 via entrez): RS1000003050 (3:32065775 G>T), RS1000028738 (3:32045909 G>T), RS1000035986 (3:32000455 A>G), RS1000036916 (3:31834429 C>T), RS1000060348 (3:32008690 C>A,T), RS1000061168 (3:31942154 A>G), RS1000062644 (3:31759176 T>C), RS1000078867 (3:31912118 G>A,C), RS1000091764 (3:31759454 T>C), RS1000097830 (3:31928941 T>C), RS1000123592 (3:31951699 T>C), RS1000124234 (3:31688728 C>A), RS1000128097 (3:32024415 T>C), RS1000138677 (3:31854218 G>C), RS1000140196 (3:31834942 T>A)

Disease associations

OMIM: gene MIM:606738 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST000720_2	Peripheral artery disease	5.000000e-07
GCST002312_8	Periodontal disease-related phenotype (Socransky)	6.000000e-06
GCST009364_27	Triglyceride levels x long total sleep time interaction (2df test)	8.000000e-10
GCST012174_1	Diabetic retinopathy in type 2 diabetes	7.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	9
trichostatin A	increases expression, affects cotreatment	3
sodium arsenite	increases expression, decreases expression, affects cotreatment, increases abundance	3
Benzo(a)pyrene	affects methylation, increases expression	3
Tetrachlorodibenzodioxin	increases expression	3
entinostat	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Acetaminophen	increases expression	2
Cisplatin	affects expression, decreases expression	2
Doxorubicin	decreases expression, affects response to substance	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Cyclosporine	increases expression	2
Aflatoxin B1	decreases methylation	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
testosterone undecanoate	affects cotreatment, increases expression	1
beta-lapachone	decreases expression, increases expression	1
arsenite	affects binding, decreases reaction	1
9,10-dihydro-9,10-dihydroxybenzo(a)pyrene	increases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
ferrous chloride	increases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Decitabine	affects expression	1
Sunitinib	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.